CRT Pioneer fund, BACIT and SAREUM agree to cancer drug funding
25 September 2013 | By Cancer Research UK
Trio enter into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.
List view / Grid view
25 September 2013 | By Cancer Research UK
Trio enter into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.
23 September 2013 | By Cancer Research UK
Dr Simon Boulton has been named as one of the recipients of the 2013 Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center in America...
16 September 2013 | By Cancer Research Technology Ltd.
Cancer Research Technology and Teva Pharmaceutical have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells...
9 July 2013 | By AstraZeneca
AstraZeneca enters agreement with University of Cambridge & Cancer Research UK...
31 May 2013 | By Cancer Research UK
A LACK of clinical trials aimed specifically at younger breast cancer patients could be partly to blame for their poorer survival rates...
3 August 2011 | By Cancer Research UK
CANCER RESEARCH UK scientists have developed a new imaging technique...
20 May 2011 | By Cancer Research UK
Cancer Research scientists discover that stopping prostate cancer cells ‘bulking up’ with nutrients reduces spread of the disease...
20 March 2009 | By
Technological advances in robotised microscopy, liquid handling and image processing have enabled the emergence of high content screening where large numbers of specimens are automatically analysed. Here we overview the process discussing potential difficulties and solutions.
Sally Burtles, Stephen Freestone and Eddie Caffrey discuss the future direction for clinical trials, covering the main challenges faced in the current application of Phase I clinical trials, changes the industry be implementing in order to further improve the efficiency of early clinical trials and how the Regulatory bodies’ guidance…